Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Bladder Cancer, January 2018

Free Subscription


Abstracts

Retrieve all available abstracts of the following 191 articles:
HTML format


 

Single Articles

  1. PENG F, Li H, Xiao H, Li L, et al
    Identification of a three miRNA signature as a novel potential prognostic biomarker in patients with bladder cancer.
    Oncotarget. 2017;8:105553-105560.
    Abstract    

    Abstract available

  2. HO JN, Kang M, Lee S, Oh JJ, et al
    Anticancer effect of S-allyl-L-cysteine via induction of apoptosis in human bladder cancer cells.
    Oncol Lett. 2018;15:623-629.
    Abstract    

    Abstract available

  3. SELINSKI S
    Discovering urinary bladder cancer risk variants: Status quo after almost ten years of genome-wide association studies.
    EXCLI J. 2017;16:1288-1296.
    Abstract    



  4. SUNDAHL N, Rottey S, De Maeseneer D, Ost P, et al
    Pembrolizumab for the treatment of bladder cancer.
    Expert Rev Anticancer Ther. 2017 Dec 29:1-8. doi: 10.1080/14737140.2018.1421461.
    Abstract    

    Abstract available

  5. AFSHARMOGHADAM N, Haghighatian Z, Mazdak H, Mirkheshti N, et al
    Concentration- Dependent Effects of Curcumin on 5-Fluorouracil Efficacy in Bladder Cancer Cells
    Asian Pac J Cancer Prev. 2017;18:3225-3230.
    Abstract    

    Abstract available

  6. NEOH CA, Wu WT, Dai GF, Su JH, et al
    Flaccidoxide-13-Acetate Extracted from the Soft Coral Cladiella kashmani Reduces Human Bladder Cancer Cell Migration and Invasion through Reducing Activation of the FAK/PI3K/AKT/mTOR Signaling Pathway.
    Molecules. 2017;23.
    Abstract    

    Abstract available

  7. GUERCIO V, Turati F, Bosetti C, Polesel J, et al
    Bladder cancer risk in users of selected drugs for cardiovascular disease prevention.
    Eur J Cancer Prev. 2017 Dec 26. doi: 10.1097/CEJ.0000000000000419.
    Abstract    

    Abstract available

  8. ZHANG Q, Wang W, Xu W, DU M, et al
    Genetic Variations in the 3'-untranslated Regions of Genes Involved in the Cell Cycle and Apoptosis Pathways Affect Bladder Cancer Risk.
    Cancer Genomics Proteomics. 2018;15:67-72.
    Abstract    

    Abstract available

  9. SIRACUSANO S, D'Elia C, Cerruto MA, Saleh O, et al
    Quality of Life in Patients with Bladder Cancer Undergoing Ileal Conduit: A Comparison of Women Versus Men.
    In Vivo. 2018;32:139-143.
    Abstract    

    Abstract available

  10. LEE YH, Yeh CH
    Laminar shear stress inhibits high glucose-induced migration and invasion in human bladder cancer cells.
    In Vitro Cell Dev Biol Anim. 2017 Dec 22. pii: 10.1007/s11626-017-0217.
    Abstract    

    Abstract available

  11. SUSSMAN RD, Han CJ, Marchalik D, Carvahlo FL, et al
    To oophorectomy or not to oophorectomy: Practice patterns among urologists treating bladder cancer.
    Urol Oncol. 2017 Dec 19. pii: S1078-1439(17)30606.
    Abstract    

    Abstract available

  12. JUNG YL, Tompa E, Longo C, Kalcevich C, et al
    The Economic Burden of Bladder Cancer due to Occupational Exposure.
    J Occup Environ Med. 2017 Dec 21. doi: 10.1097/JOM.0000000000001242.
    Abstract    

    Abstract available

  13. LI B, Xie F, Zheng FX, Jiang GS, et al
    Overexpression of CircRNA BCRC4 regulates cell apoptosis and MicroRNA-101/EZH2 signaling in bladder cancer.
    J Huazhong Univ Sci Technolog Med Sci. 2017;37:886-890.
    Abstract    

    Abstract available

  14. PRICE L, Glynn P, Zarkar A
    Interstitial lung disease secondary to Cetuximab in bladder cancer: an Oncologist's perspective.
    BMJ Case Rep. 2017;2017.
    Abstract    

    Abstract available

  15. PAVANELLO S, Carta A, Mastrangelo G, Campisi M, et al
    Relationship between Telomere Length, Genetic Traits and Environmental/Occupational Exposures in Bladder Cancer Risk by Structural Equation Modelling.
    Int J Environ Res Public Health. 2017;15.
    Abstract    

    Abstract available

  16. SAADI A, Bouzouita A, Rebai MH, Cherif M, et al
    Superselective embolisation of bilateral superior vesical arteries for management of intractable hematuria in context of metastatic bladder cancer.
    Asian J Urol. 2017;4:131-134.
    Abstract    

    Abstract available

  17. OKHOLM TLH, Nielsen MM, Hamilton MP, Christensen LL, et al
    Circular RNA expression is abundant and correlated to aggressiveness in early-stage bladder cancer.
    NPJ Genom Med. 2017;2:36.
    Abstract    

    Abstract available

  18. LIU D, Abbosh P, Keliher D, Reardon B, et al
    Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer.
    Nat Commun. 2017;8:2193.
    Abstract    

    Abstract available

  19. DHAINI HR, El Hafi B, Khamis AM
    NAT1 genotypic and phenotypic contribution to urinary bladder cancer risk: a systematic review and meta-analysis.
    Drug Metab Rev. 2017 Dec 19:1-12. doi: 10.1080/03602532.2017.1415928.
    Abstract    

    Abstract available

  20. KANDEMIRLI SG, Dikici AS, Nurili F, Tutar O, et al
    Bladder cancer in an inguinal vesical hernia.
    J Med Ultrason (2001). 2017 Dec 18. pii: 10.1007/s10396-017-0854.
    Abstract    

    Abstract available

  21. HURST CD, Knowles MA
    Bladder cancer: Multi-omic profiling refines the molecular view.
    Nat Rev Clin Oncol. 2017 Dec 19. pii: nrclinonc.2017.
    Abstract    



  22. MATSUMOTO K, Tabata KI, Hirayama T, Shimura S, et al
    Robot-assisted laparoscopic radical cystectomy is a safe and effective procedure for patients with bladder cancer compared to laparoscopic and open surgery: Perioperative outcomes of a single-center experience.
    Asian J Surg. 2017 Dec 15. pii: S1015-9584(17)30518.
    Abstract    

    Abstract available

  23. BOOTH CM, Karim S, Brennan K, Siemens DR, et al
    Perioperative chemotherapy for bladder cancer in the general population: Are practice patterns finally changing?
    Urol Oncol. 2017 Dec 15. pii: S1078-1439(17)30603.
    Abstract    

    Abstract available

  24. XU X, Li J, Zhu Y, Xie B, et al
    CRISPR-ON-Mediated KLF4 overexpression inhibits the proliferation, migration and invasion of urothelial bladder cancer in vitro and in vivo.
    Oncotarget. 2017;8:102078-102087.
    Abstract    

    Abstract available

  25. KLITON J, Polgar C, Tenke P, Kovacs G, et al
    [Image-guided radiotherapy for muscle invasive bladder cancer with intravesical lipiodol injection. A new option for bladder sparing treatment].
    Orv Hetil. 2017;158:2041-2047.
    Abstract    

    Abstract available

  26. CIAMPORCERO E, Daga M, Pizzimenti S, Roetto A, et al
    Crosstalk between Nrf2 and YAP contributes to maintaining the antioxidant potential and chemoresistance in bladder cancer.
    Free Radic Biol Med. 2017 Dec 14. pii: S0891-5849(17)31237.
    Abstract    

    Abstract available

  27. WANG Z, Que H, Suo C, Han Z, et al
    Evaluation of the NMP22 BladderChek test for detecting bladder cancer: a systematic review and meta-analysis.
    Oncotarget. 2017;8:100648-100656.
    Abstract    

    Abstract available

  28. KO K, Jeong CW, Kwak C, Kim HH, et al
    Significance of Ki-67 in non-muscle invasive bladder cancer patients: a systematic review and meta-analysis.
    Oncotarget. 2017;8:100614-100630.
    Abstract    

    Abstract available

  29. CHAN OTM, Furuya H, Pagano I, Shimizu Y, et al
    Association of MMP-2, RB and PAI-1 with decreased recurrence-free survival and overall survival in bladder cancer patients.
    Oncotarget. 2017;8:99707-99721.
    Abstract    

    Abstract available

  30. XIAOQIANG L, Xuerong Z, Juan L, Mathew BS, et al
    Efficacy of pudendal nerve block for alleviation of catheter-related bladder discomfort in male patients undergoing lower urinary tract surgeries: A randomized, controlled, double-blind trial.
    Medicine (Baltimore). 2017;96:e8932.
    Abstract    

    Abstract available

  31. TOUZANI MA, Yddoussalah O
    [Cavernous metastasis from blader tumor].
    Pan Afr Med J. 2017;28:60.
    Abstract    

    Abstract available

  32. SAXE JS
    Denial.
    Ann Intern Med. 2017;167:828-829.
    Abstract    



  33. DAVIDSSON S, Andren O, Ohlson AL, Carlsson J, et al
    FOXP3+ regulatory T cells in normal prostate tissue, postatrophic hyperplasia, prostatic intraepithelial neoplasia, and tumor histological lesions in men with and without prostate cancer.
    Prostate. 2017 Nov 6. doi: 10.1002/pros.23442.
    Abstract    

    Abstract available

  34. INOUE A, Maeda S, Kinoshita R, Tsuboi M, et al
    Density of tumor-infiltrating granzyme B-positive cells predicts favorable prognosis in dogs with transitional cell carcinoma.
    Vet Immunol Immunopathol. 2017;190:53-56.
    Abstract    

    Abstract available

  35. CHARGARI C, Martelli H, Guerin F, Bacorro W, et al
    Pulsed-dose rate brachytherapy for pediatric bladder prostate rhabdomyosarcoma: Compliance and early clinical results.
    Radiother Oncol. 2017;124:285-290.
    Abstract    

    Abstract available

  36. INAMURA K, Kobayashi M, Nagano H, Sugiura Y, et al
    A novel fusion of HNRNPA1-ALK in inflammatory myofibroblastic tumor of urinary bladder.
    Hum Pathol. 2017;69:96-100.
    Abstract    

    Abstract available

  37. DIETRICH F, Figueiro F, Filippi-Chiela EC, Cappellari AR, et al
    Ecto-5'-nucleotidase/CD73 contributes to the radiosensitivity of T24 human bladder cancer cell line.
    J Cancer Res Clin Oncol. 2018 Jan 5. pii: 10.1007/s00432-017-2567.
    Abstract    

    Abstract available

  38. YU Z, Yue W, Jiuzhi L, Youtao J, et al
    The risk of bladder cancer in patients with urinary calculi: a meta-analysis.
    Urolithiasis. 2018 Jan 5. pii: 10.1007/s00240-017-1033.
    Abstract    

    Abstract available

  39. WU S, Ye J, Wang Z, Lin SX, et al
    Expression of aromatase in tumor related stroma is associated with human bladder cancer progression.
    Cancer Biol Ther. 2018 Jan 5:0. doi: 10.1080/15384047.2017.1414762.
    Abstract    

    Abstract available

  40. COLLINS SD, Leech MM
    A review of plan library approaches in adaptive radiotherapy of bladder cancer.
    Acta Oncol. 2018 Jan 4:1-8. doi: 10.1080/0284186X.2017.1420908.
    Abstract    

    Abstract available

  41. ROSAS S, Sabeh K, Kurowicki J, Buller L, et al
    National use of total hip arthroplasty among patients with a history of breast, lung, prostate, colon or bladder cancer-an analysis of the Medicare population.
    Ann Transl Med. 2017;5.
    Abstract    

    Abstract available

  42. SEGOVIA C, Paramio JM
    Ezh2-dependent therapies in bladder cancer: synthetic lethality.
    Ann Transl Med. 2017;5:494.
    Abstract    



  43. JUENGEL E, Najafi R, Rutz J, Maxeiner S, et al
    HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells.
    Oncotarget. 2017;8:110016-110028.
    Abstract    

    Abstract available

  44. LIAO XZ, Tao LT, Liu JH, Gu YY, et al
    Matrine combined with cisplatin synergistically inhibited urothelial bladder cancer cells via down-regulating VEGF/PI3K/Akt signaling pathway.
    Cancer Cell Int. 2017;17:124.
    Abstract    

    Abstract available

  45. ZHANG L, Xu J, Yang G, Li H, et al
    miR-202 inhibits cell proliferation, migration, and invasion by targeting EGFR in human bladder cancer.
    Oncol Res. 2018 Jan 3. doi: 10.3727/096504018X15149787144385.
    Abstract    

    Abstract available

  46. THOMA C
    Bladder cancer: IMvigor211 trial outcomes reported.
    Nat Rev Urol. 2018 Jan 3. pii: nrurol.2017.225. doi: 10.1038/nrurol.2017.
    Abstract    



  47. THOMA C
    Bladder cancer: Chemotherapy and checkpoint blockade.
    Nat Rev Urol. 2018 Jan 3. pii: nrurol.2017.224. doi: 10.1038/nrurol.2017.
    Abstract    



  48. THOMA C
    Bladder cancer: Activity and safety of avelumab in JAVELIN.
    Nat Rev Urol. 2018 Jan 3. pii: nrurol.2017.227. doi: 10.1038/nrurol.2017.
    Abstract    



  49. ZUIVERLOON TCM, de Jong FC, Theodorescu D
    Clinical Decision Making in Surveillance of Non-Muscle-Invasive Bladder Cancer: The Evolving Roles of Urinary Cytology and Molecular Markers.
    Oncology (Williston Park). 2017;31.
    Abstract    

    Abstract available

  50. KIM SJ, Koo PJ, Pak K, Kim IJ, et al
    Diagnostic accuracy of C-11 choline and C-11 acetate for lymph node staging in patients with bladder cancer: a systematic review and meta-analysis.
    World J Urol. 2018 Jan 2. pii: 10.1007/s00345-017-2168.
    Abstract    

    Abstract available

  51. HARSHMAN LC, Tripathi A, Kaag M, Efstathiou JA, et al
    Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer.
    Clin Genitourin Cancer. 2017 Dec 6. pii: S1558-7673(17)30364.
    Abstract    

    Abstract available

  52. ROSE TL, Lotan Y
    Advancements in optical techniques and imaging in the diagnosis and management of bladder cancer.
    Urol Oncol. 2017 Dec 26. pii: S1078-1439(17)30602.
    Abstract    

    Abstract available

  53. YOSHIDA T, Kates M, Sopko NA, Liu X, et al
    Ex vivo culture of tumor cells from N-methyl-N-nitrosourea-induced bladder cancer in rats: Development of organoids and an immortalized cell line.
    Urol Oncol. 2017 Dec 26. pii: S1078-1439(17)30618.
    Abstract    

    Abstract available

  54. ALJABERY F, Olsson H, Gimm O, Jahnson S, et al
    M2-macrophage infiltration and macrophage traits of tumor cells in urinary bladder cancer.
    Urol Oncol. 2017 Dec 26. pii: S1078-1439(17)30608.
    Abstract    

    Abstract available

  55. OSTERMAN CK, Alanzi J, Lewis JD, Kaufman EL, et al
    Association Between Symptomatic Versus Asymptomatic Recurrence and Survival in Bladder Cancer.
    Clin Genitourin Cancer. 2017 Dec 6. pii: S1558-7673(17)30361.
    Abstract    

    Abstract available

  56. NKWAM N, Trecarten S, Momcilovic S, Bazo AE, et al
    Isolated red patches seen during endoscopic surveillance of bladder cancer - when should we biopsy?
    J Endourol. 2017 Dec 29. doi: 10.1089/end.2017.0744.
    Abstract    

    Abstract available

  57. GOLABEK T, Socha K, Kudelski J, Darewicz B, et al
    Chromium in urothelial carcinoma of the bladder.
    Ann Agric Environ Med. 2017;24:602-605.
    Abstract    

    Abstract available

  58. HEIN DW, Zhang X, Doll MA
    Role of N-acetyltransferase 2 acetylation polymorphism in 4, 4'-methylene bis (2-chloroaniline) biotransformation.
    Toxicol Lett. 2018;283:100-105.
    Abstract    

    Abstract available

  59. ARIAS-STELLA JA 3RD, Shah AB, Gupta NS, Williamson SR, et al
    CK20 and p53 Immunohistochemical Staining Patterns in Urinary Bladder Specimens With Equivocal Atypia.
    Arch Pathol Lab Med. 2018;142:64-69.
    Abstract    

    Abstract available

  60. YANG G, Wang Z, Liu S, Wu F, et al
    A Rare Case of Urachal Carcinoma Metastatic to Thoracic Vertebra Detected by FDG PET/CT.
    Clin Nucl Med. 2017 May 5. doi: 10.1097/RLU.0000000000001680.
    Abstract    

    Abstract available

  61. ROY SG, Parida GK, Tripathy S, Singhal A, et al
    In Vivo Demonstration of PSMA Expression in Adenocarcinoma Urinary Bladder Using 68Ga-PSMA 11 PET/CT.
    Clin Nucl Med. 2017 May 6. doi: 10.1097/RLU.0000000000001683.
    Abstract    

    Abstract available

  62. YANG AW, Pooli A, Lele SM, Kim IW, et al
    Lymphoepithelioma-like, a variant of urothelial carcinoma of the urinary bladder: a case report and systematic review for optimal treatment modality for disease-free survival.
    BMC Urol. 2017;17:34.
    Abstract    

    Abstract available

  63. TAN WS, Lamb BW, Sridhar A, Briggs TP, et al
    A comprehensive guide to perioperative management and operative technique for robotic cystectomy with intracorporeal urinary diversion.
    Urologia. 2017;84:71-78.
    Abstract    

    Abstract available

  64. CHANG E, Sabichi AL, Sada YH
    Myasthenia Gravis After Nivolumab Therapy for Squamous Cell Carcinoma of the Bladder.
    J Immunother. 2017;40:114-116.
    Abstract    

    Abstract available

  65. LIZEE D, Salas RS, Barret E, Galiano M, et al
    Impact of neoadjuvant chemotherapy on complications of minimally invasive radical cystectomy.
    Actas Urol Esp. 2017;41:88-96.
    Abstract    

    Abstract available

  66. KANASHIRO A, Gaya JM, Palou J, Gausa L, et al
    Robot-assisted radical cystoprostatectomy: Analysis of the complications and oncological and functional aspects.
    Actas Urol Esp. 2017;41:267-273.
    Abstract    

    Abstract available

  67. LIU J, Bi J, Li Z, Li Z, et al
    miR214 reduces cisplatin resistance by targeting netrin1 in bladder cancer cells.
    Int J Mol Med. 2018 Jan 10. doi: 10.3892/ijmm.2018.3374.
    Abstract    

    Abstract available

  68. GLEICHENHAGEN J, Arndt C, Casjens S, Meinig C, et al
    Evaluation of a New Survivin ELISA and UBC((R)) Rapid for the Detection of Bladder Cancer in Urine.
    Int J Mol Sci. 2018;19.
    Abstract    

    Abstract available

  69. BAKER SC, Arlt VM, Indra R, Joel M, et al
    Differentiation-associated urothelial cytochrome P450 oxidoreductase predicates the xenobiotic-metabolising activity of "luminal" muscle-invasive bladder cancers.
    Mol Carcinog. 2018 Jan 11. doi: 10.1002/mc.22784.
    Abstract    

    Abstract available

  70. POLETAJEW S, Biernacki R, Buraczynski P, Chojnacki J, et al
    Predictors and prognostic implications of clinical decisions in patients with primary high-risk non-muscle-invasive bladder cancer - results of a cross country retrospective study.
    Neoplasma. 2018;65:147-152.
    Abstract    

    Abstract available

  71. GAO L, Yan P, Guo FF, Liu HJ, et al
    MiR-1-3p inhibits cell proliferation and invasion by regulating BDNF-TrkB signaling pathway in bladder cancer.
    Neoplasma. 2018;65:89-96.
    Abstract    

    Abstract available

  72. WANG B, Wan F, Sheng H, Zhu Y, et al
    Identification and validation of an 18-gene signature highly-predictive of bladder cancer metastasis.
    Sci Rep. 2018;8:374.
    Abstract    

    Abstract available

  73. GUO P, Zhang G, Meng J, He Q, et al
    Upregulation of long non-coding RNA TUG1 promotes bladder cancer cell 5 proliferation, migration and invasion by inhibiting miR-29c.
    Oncol Res. 2018 Jan 10. doi: 10.3727/096504018X15152085755247.
    Abstract    

    Abstract available

  74. ZHAI X, Xu W
    Long noncoding RNA ATB promotes proliferation, migration and invasion in bladder cancer by suppressing microRNA-126.
    Oncol Res. 2018 Jan 10. doi: 10.3727/096504018X15152072098476.
    Abstract    

    Abstract available

  75. WALKER M, Doiron RC, French SD, Feldman-Stewart D, et al
    Perioperative chemotherapy for bladder cancer: A qualitative study of physician knowledge, attitudes, and behaviour.
    Can Urol Assoc J. 2017 Dec 22. pii: cuaj.4791. doi: 10.5489/cuaj.4791.
    Abstract    

    Abstract available

  76. YOO CH
    The Author's Response: Bioinformatics Analysis in Downstream Genes of the mTOR Pathway to Predict Recurrence and Progression of Bladder Cancer.
    J Korean Med Sci. 2018;33:e32.
    Abstract    



  77. LI C, Liu H, Xu Y
    Letter to the Editor: Bioinformatics Analysis in Downstream Genes of the mTOR Pathway to Predict Recurrence and Progression of Bladder Cancer.
    J Korean Med Sci. 2018;33:e31.
    Abstract    



  78. LONG Q, Lin TY, Huang Y, Li X, et al
    Imaging-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model.
    Nanomedicine. 2018 Jan 6. pii: S1549-9634(17)30592.
    Abstract    

    Abstract available

  79. WANG F, Tang J, Li P, Si S, et al
    Chloroquine Enhances the Radiosensitivity of Bladder Cancer Cells by Inhibiting Autophagy and Activating Apoptosis.
    Cell Physiol Biochem. 2017;45:54-66.
    Abstract    

    Abstract available

  80. SALEM J, Paffenholz P, Bolenz C, von Brandenstein M, et al
    Websites on Bladder Cancer: an Appropriate Source of Patient Information?
    J Cancer Educ. 2018 Jan 8. pii: 10.1007/s13187-017-1316.
    Abstract    

    Abstract available

  81. VAN DER POL CB, Shinagare AB, Tirumani SH, Preston MA, et al
    Bladder cancer local staging: multiparametric MRI performance following transurethral resection.
    Abdom Radiol (NY). 2018 Jan 9. pii: 10.1007/s00261-017-1449.
    Abstract    

    Abstract available

  82. ZHANG L, Yang G, Chen H, Huang Y, et al
    Depletion of astrocyte elevated gene-1 suppresses tumorigenesis through inhibition of Akt activity in bladder cancer cells.
    Am J Transl Res. 2017;9:5422-5431.
    Abstract    

    Abstract available

  83. SAAD FT, Hincal E, Kaymakamzade B
    Dynamics of Immune Checkpoints, Immune System, and BCG in the Treatment of Superficial Bladder Cancer.
    Comput Math Methods Med. 2017;2017:3573082.
    Abstract    

    Abstract available

  84. GHATE K, Brennan K, Karim S, Siemens DR, et al
    Concurrent chemoradiotherapy for bladder cancer: Practice patterns and outcomes in the general population.
    Radiother Oncol. 2018 Jan 3. pii: S0167-8140(17)32764.
    Abstract    

    Abstract available

  85. COSTA-MARTINEZ MA, Prieto Vita M, Garces Proano LE, Carro Rubias C, et al
    [Neurofibromas in the urogenital system: Report of two cases and literature review.]
    Arch Esp Urol. 2017;70:796-799.
    Abstract    

    Abstract available

  86. JING Y, Zhang R, Ma P, Cai MC, et al
    Prevalence and clonality of synchronous primary carcinomas in the bladder and prostate.
    J Pathol. 2018;244:5-10.
    Abstract    

    Abstract available

  87. YU SS, Ballas LK, Skinner EC, Dorff TB, et al
    Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment.
    Clin Adv Hematol Oncol. 2017;15:543-551.
    Abstract    

    Abstract available

  88. PFARR N, Darb-Esfahani S, Leichsenring J, Taube E, et al
    Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology.
    Genes Chromosomes Cancer. 2017;56:758-766.
    Abstract    

    Abstract available

  89. NGUYEN VP, Park S, Oh J, Wook Kang H, et al
    Biocompatible astaxanthin as novel contrast agent for biomedical imaging.
    J Biophotonics. 2017;10:1053-1061.
    Abstract    

    Abstract available

  90. MAO XW, Xiao JQ, Li ZY, Zheng YC, et al
    Effects of microRNA-135a on the epithelial-mesenchymal transition, migration and invasion of bladder cancer cells by targeting GSK3beta through the Wnt/beta-catenin signaling pathway.
    Exp Mol Med. 2018;50:e429.
    Abstract    

    Abstract available

  91. LI YP, Jia XP, Jiang YQ, Wang W, et al
    Differential expression of cytokeratin 14 and 18 in bladder cancer tumorigenesis.
    Exp Biol Med (Maywood). 2018 Jan 1:1535370218754493.
    Abstract    

    Abstract available

  92. YANG HJ, Liu GL, Liu B, Liu T, et al
    GP73 promotes invasion and metastasis of bladder cancer by regulating the epithelial-mesenchymal transition through the TGF-beta1/Smad2 signalling pathway.
    J Cell Mol Med. 2018 Jan 19. doi: 10.1111/jcmm.13442.
    Abstract    

    Abstract available

  93. SINGH R, Mandhani A, Agrawal V, Garg M, et al
    Positive Correlation between Matrix Metalloproteinases and Epithelial-to-Mesenchymal Transition and its Association with Clinical Outcome in Bladder Cancer Patients.
    Cancer Microenviron. 2018 Jan 18. pii: 10.1007/s12307-017-0199.
    Abstract    

    Abstract available

  94. JI L, Zhong B, Jiang X, Mao F, et al
    Actein induces autophagy and apoptosis in human bladder cancer by potentiating ROS/JNK and inhibiting AKT pathways.
    Oncotarget. 2017;8:112498-112515.
    Abstract    

    Abstract available

  95. WONG MCS, Fung FDH, Leung C, Cheung WWL, et al
    The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection.
    Sci Rep. 2018;8:1129.
    Abstract    

    Abstract available

  96. PHELAN A, Lopez-Beltran A, Montironi R, Zhang S, et al
    Inherited forms of bladder cancer: a review of lynch syndrome and other inherited conditions.
    Future Oncol. 2018 Jan 18. doi: 10.2217/fon-2017-0346.
    Abstract    

    Abstract available

  97. KITCHEN MO, Bryan RT, Emes RD, Luscombe CJ, et al
    HumanMethylation450K Array-Identified Biomarkers Predict Tumour Recurrence/Progression at Initial Diagnosis of High-risk Non-muscle Invasive Bladder Cancer.
    Biomark Cancer. 2018;10:1179299X17751920.
    Abstract    

    Abstract available

  98. PATEL SG, Weiner AB, Keegan K, Morgan T, et al
    Oncologic outcomes in patients with nonurothelial bladder cancer.
    Indian J Urol. 2018;34:39-44.
    Abstract    

    Abstract available

  99. RAYN KN, Hale GR, Grave GP, Agarwal PK, et al
    New therapies in nonmuscle invasive bladder cancer treatment.
    Indian J Urol. 2018;34:11-19.
    Abstract    

    Abstract available

  100. CHOI JB, Lee EJ, Han KD, Hong SH, et al
    Estimating the impact of body mass index on bladder cancer risk: Stratification by smoking status.
    Sci Rep. 2018;8:947.
    Abstract    

    Abstract available

  101. MCCONKEY DJ, Choi W
    Subtyping Bladder Cancers: Biology vs Bioinformatics.
    J Natl Cancer Inst. 2018 Jan 12. pii: 4804358. doi: 10.1093.
    Abstract    



  102. OGIHARA K, Kikuchi E, Watanabe K, Kufukihara R, et al
    Can urologists introduce the concept of "oligometastasis" for metastatic bladder cancer after total cystectomy?
    Oncotarget. 2017;8:111819-111835.
    Abstract    

    Abstract available

  103. WANG C, Chen L, Yang Y, Zhang M, et al
    Identification of bladder cancer prognostic biomarkers using an ageing gene-related competitive endogenous RNA network.
    Oncotarget. 2017;8:111742-111753.
    Abstract    

    Abstract available

  104. XIN Z, Yang Z, Xu J, Li C, et al
    Gene expression profiling and construction of a putative gene regulatory network of bladder cancer tumor-initiating cells.
    Oncotarget. 2017;8:111271-111280.
    Abstract    

    Abstract available

  105. WEINER AB, Keeter MK, Manjunath A, Meeks JJ, et al
    Discrepancies in staging, treatment, and delays to treatment may explain disparities in bladder cancer outcomes: An update from the National Cancer Data Base (2004-2013).
    Urol Oncol. 2018 Jan 12. pii: S1078-1439(17)30644.
    Abstract    

    Abstract available

  106. PENG D, Zhang CJ, Gong YQ, Hao H, et al
    Prognostic significance of HALP (hemoglobin, albumin, lymphocyte and platelet) in patients with bladder cancer after radical cystectomy.
    Sci Rep. 2018;8:794.
    Abstract    

    Abstract available

  107. ZAPALA P, Dybowski B, Poletajew S, Bialek L, et al
    Clinical rationale and safety of restaging transurethral resection in indication-stratified patients with high-risk non-muscle-invasive bladder cancer.
    World J Surg Oncol. 2018;16:6.
    Abstract    

    Abstract available

  108. MACLENNAN MS, Kok MGM, Soliman L, So A, et al
    Capillary electrophoresis-mass spectrometry for targeted and untargeted analysis of the sub-5kDa urine metabolome of patients with prostate or bladder cancer: A feasibility study.
    J Chromatogr B Analyt Technol Biomed Life Sci. 2018;1074-1075:79-85.
    Abstract    

    Abstract available

  109. HEINER SM, Viers BR, Rivera ME, Linder BJ, et al
    What is the fate of artificial urinary sphincters among men undergoing repetitive bladder cancer treatment?
    Investig Clin Urol. 2018;59:44-48.
    Abstract    

    Abstract available

  110. BOLT HM
    Highlight report: Occupational urinary bladder cancer.
    EXCLI J. 2017;16:1319-1320.
    Abstract    



  111. ARAUJO JE, Lopez-Fernandez H, Diniz MS, Baltazar PM, et al
    Dithiothreitol-based protein equalization technology to unravel biomarkers for bladder cancer.
    Talanta. 2018;180:36-46.
    Abstract    

    Abstract available

  112. YANG X, Zhao L, Li M, Yan L, et al
    Lidocaine enhances the effects of chemotherapeutic drugs against bladder cancer.
    Sci Rep. 2018;8:598.
    Abstract    

    Abstract available

  113. YU SS, Dorff TB, Ballas LK, Sadeghi S, et al
    Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease.
    Clin Adv Hematol Oncol. 2017;15:466-477.
    Abstract    

    Abstract available

  114. CANNIOTO R, Etter JL, Guterman LB, Joseph JM, et al
    The association of lifetime physical inactivity with bladder and renal cancer risk: A hospital-based case-control analysis.
    Cancer Epidemiol. 2017;49:24-29.
    Abstract    

    Abstract available

  115. QAMAR S, Inam QA, Ashraf S, Khan MS, et al
    Prognostic Value of p53 Expression Intensity in Urothelial Cancers.
    J Coll Physicians Surg Pak. 2017;27:232-236.
    Abstract    

    Abstract available

  116. CALISKAN S, Sungur M
    Bladder Leiomyoma.
    J Coll Physicians Surg Pak. 2017;27:189-190.
    Abstract    

    Abstract available

  117. MARIEN A, Rock A, Maadarani KE, Francois C, et al
    Urothelial Tumors and Dual-Band Imaging: A New Concept in Confocal Laser Endomicroscopy.
    J Endourol. 2017;31:538-544.
    Abstract    

    Abstract available

  118. LE GOUX C, Damotte D, Vacher S, Sibony M, et al
    Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
    Urol Oncol. 2017;35:257-263.
    Abstract    

    Abstract available

  119. USAWACHINTACHIT M, Isaacson DS, Taguchi K, Tzou DT, et al
    A Prospective Case-Control Study Comparing LithoVue, a Single-Use, Flexible Disposable Ureteroscope, with Flexible, Reusable Fiber-Optic Ureteroscopes.
    J Endourol. 2017;31:468-475.
    Abstract    

    Abstract available

  120. CASADIO V, Salvi S, Martignano F, Gunelli R, et al
    Cell-Free DNA Integrity Analysis in Urine Samples.
    J Vis Exp. 2017;.
    Abstract    

    Abstract available

  121. KARABULUT YY, Erdogan S, Sayar H, Ergen A, et al
    Primary malignant melanoma of the urinary bladder: clinical, morphological, and molecular analysis of five cases.
    Melanoma Res. 2016.
    Abstract    

    Abstract available

  122. MITHANI MH, Khan SA, Khalid SE, Siddique R, et al
    Awareness of risk factors and fallacies associated with urinary bladder cancer in our population: A prospective survey.
    J Pak Med Assoc. 2018;68:55-58.
    Abstract    

    Abstract available

  123. LI Y, Diao F, Shi S, Li K, et al
    Computed tomography and magnetic resonance imaging evaluation of pelvic lymph node metastasis in bladder cancer.
    Chin J Cancer. 2018;37:3.
    Abstract    

    Abstract available

  124. MOSCHINI M, Mattei A, Cornelius J, Shariat SF, et al
    Surgical treatment for clinical node-positive bladder cancer patients treated with radical cystectomy without neoadjuvant chemotherapy.
    World J Urol. 2018 Jan 24. pii: 10.1007/s00345-018-2190.
    Abstract    

    Abstract available

  125. KHANDELWAL M, Anand V, Appunni S, Seth A, et al
    Decitabine augments cytotoxicity of cisplatin and doxorubicin to bladder cancer cells by activating hippo pathway through RASSF1A.
    Mol Cell Biochem. 2018 Jan 24. pii: 10.1007/s11010-018-3278.
    Abstract    

    Abstract available

  126. BUTT SU, Malik L
    Role of immunotherapy in bladder cancer: past, present and future.
    Cancer Chemother Pharmacol. 2018 Jan 24. pii: 10.1007/s00280-018-3518.
    Abstract    

    Abstract available

  127. CHU M, Zhang C
    Inhibition of angiogenesis by leflunomide via targeting the soluble ephrin-A1/EphA2 system in bladder cancer.
    Sci Rep. 2018;8:1539.
    Abstract    

    Abstract available

  128. NIWA N, Matsumoto K, Ide H, Nagata H, et al
    Prognostic Value of Pretreatment Albumin-to-Globulin Ratio in Patients With Non-Muscle-Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2018 Jan 4. pii: S1558-7673(18)30001.
    Abstract    

    Abstract available

  129. GOGALIC S, Sauer U, Doppler S, Preininger C, et al
    Investigating Colorimetric Protein Array Assay Schemes for Detection of Recurrence of Bladder Cancer.
    Biosensors (Basel). 2018;8.
    Abstract    

    Abstract available

  130. POLETAJEW S, Wolinska E, Wasiutynski A, Dybowski B, et al
    [Immunohistochemical differentiation between muscularis mucosae and muscularis propria for improving the staging of bladder cancer in patients undergoing transurethral resection of bladder tumours].
    Pol J Pathol. 2017;68:218-224.
    Abstract    

    Abstract available

  131. JURACEK J, Peltanova B, Dolezel J, Fedorko M, et al
    Genome-wide identification of urinary cell-free microRNAs for non-invasive detection of bladder cancer.
    J Cell Mol Med. 2018 Jan 24. doi: 10.1111/jcmm.13487.
    Abstract    

    Abstract available

  132. CORMICK BPM, Langle Y, Belgorosky D, Vanzulli S, et al
    Flavonoid Silybin improves the response to radiotherapy in invasive bladder cancer.
    J Cell Biochem. 2018 Jan 24. doi: 10.1002/jcb.26693.
    Abstract    

    Abstract available

  133. SANGUEDOLCE F, Cormio A, Massenio P, Pedicillo MC, et al
    Altered expression of HER-2 and the mismatch repair genes MLH1 and MSH2 predicts the outcome of T1 high-grade bladder cancer.
    J Cancer Res Clin Oncol. 2018 Jan 23. pii: 10.1007/s00432-018-2593.
    Abstract    

    Abstract available

  134. KIMURA G
    [IV .The Role of Immune Checkpoint Blockade in the Treatment of Bladder Cancer].
    Gan To Kagaku Ryoho. 2018;45:38-43.
    Abstract    



  135. MIYAZAKI J
    [III .Current Status of Bladder Preservation Therapy for Muscle Invasive Bladder Cancer].
    Gan To Kagaku Ryoho. 2018;45:33-37.
    Abstract    



  136. OZONO S, Furuse H
    [II .Problems of Treatment for Non-Muscle Invasive Bladder Cancer].
    Gan To Kagaku Ryoho. 2018;45:30-32.
    Abstract    



  137. ONOZAWA M
    [I .Recent Trends in Bladder Cancer Mortality in Japan].
    Gan To Kagaku Ryoho. 2018;45:26-29.
    Abstract    



  138. AKAZA H
    [Genitourinary Tumor Four Questions about Bladder Cancer].
    Gan To Kagaku Ryoho. 2018;45:25.
    Abstract    



  139. SANLI O, Lotan Y
    Current approaches for identifying high-risk non-muscle invasive bladder cancer.
    Expert Rev Anticancer Ther. 2018 Jan 23. doi: 10.1080/14737140.2018.1432358.
    Abstract    

    Abstract available

  140. RODRIGUEZ LOPEZ S, Damas Arroyo F, Perez-Utrilla Perez MA, Lopez Sanchez D, et al
    Metastasis of Ta low-grade bladder cancer into the lung and paraneoplastic syndrome without local invasion: A case report and literature review.
    Urol Case Rep. 2017;17:17-18.
    Abstract    



  141. LIN ZR, Wang MY, He SY, Cai ZM, et al
    TACC3 transcriptionally upregulates E2F1 to promote cell growth and confer sensitivity to cisplatin in bladder cancer.
    Cell Death Dis. 2018;9:72.
    Abstract    

    Abstract available

  142. CHENG W, Fu D, Xu F, Zhang Z, et al
    Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy.
    Oncogenesis. 2018;7:2.
    Abstract    

    Abstract available

  143. HE W, Zhong G, Jiang N, Wang B, et al
    Long noncoding RNA BLACAT2 promotes bladder cancer-associated lymphangiogenesis and lymphatic metastasis.
    J Clin Invest. 2018 Jan 22. pii: 96218. doi: 10.1172/JCI96218.
    Abstract    

    Abstract available

  144. BOTELHO MC, Alves H, Richter J
    Halting Schistosoma haematobium - associated bladder cancer.
    Int J Cancer Manag. 2017;10.
    Abstract    

    Abstract available

  145. BUTTERFIELD A, Gupta S
    Next-generation sequencing in non-muscle-invasive bladder cancer-a step towards personalized medicine for a superficial bladder tumor.
    Transl Androl Urol. 2017;6:1198-1202.
    Abstract    



  146. RIETHDORF S, Soave A, Rink M
    The current status and clinical value of circulating tumor cells and circulating cell-free tumor DNA in bladder cancer.
    Transl Androl Urol. 2017;6:1090-1110.
    Abstract    

    Abstract available

  147. MARI A, D'Andrea D, Abufaraj M, Foerster B, et al
    Genetic determinants for chemo- and radiotherapy resistance in bladder cancer.
    Transl Androl Urol. 2017;6:1081-1089.
    Abstract    

    Abstract available

  148. WEZEL F, Vallo S, Roghmann F
    Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer?
    Transl Androl Urol. 2017;6:1067-1080.
    Abstract    

    Abstract available

  149. INEICHEN GB, Rothlisberger R, Johner KF, Seiler R, et al
    Different stages in drug development for muscle-invasive bladder cancer.
    Transl Androl Urol. 2017;6:1060-1066.
    Abstract    

    Abstract available

  150. PRADERE B, Thibault C, Vetterlein MW, Leow JJ, et al
    Peri-operative chemotherapy for muscle-invasive bladder cancer: status-quo in 2017.
    Transl Androl Urol. 2017;6:1049-1059.
    Abstract    

    Abstract available

  151. PANG KH, Esperto F, Noon AP
    Opportunities of next-generation sequencing in non-muscle invasive bladder cancer outcome prediction.
    Transl Androl Urol. 2017;6:1043-1048.
    Abstract    

    Abstract available

  152. DUQUESNE I, Weisbach L, Aziz A, Kluth LA, et al
    The contemporary role and impact of urine-based biomarkers in bladder cancer.
    Transl Androl Urol. 2017;6:1031-1042.
    Abstract    

    Abstract available

  153. RINK M
    The landscape of genetics and biomarkers in bladder cancer.
    Transl Androl Urol. 2017;6:1027-1030.
    Abstract    




  154. Erratum to: Hafeez S, McDonald F, Lalondrelle S, et al. Clinical outcomes of image guided adaptive hypofractionated weekly radiation therapy for bladder cancer in patients unsuitable for radical treatment. Int J Radiat Oncol Biol Phys 2017;98:115-122.
    Int J Radiat Oncol Biol Phys. 2018;100:532-533.
    Abstract    



  155. OUSATI ASHTIANI Z, Mehrsai AR, Pourmand MR, Pourmand GR, et al
    High Resolution Melting Analysis for Rapid Detection of PIK3CA Gene Mutations in Bladder Cancer: A Mutated Target for Cancer Therapy.
    Urol J. 2018 Jan 21. pii: 3987/1201.
    Abstract    

    Abstract available

  156. HORVAT N, Ragucci M, Mannelli L
    Hepatic Mass in a Patient With Bladder Cancer History.
    Gastroenterology. 2018 Jan 16. pii: S0016-5085(17)35643.
    Abstract    



  157. ZHANG ZF, Zhang HR, Zhang QY, Lai SY, et al
    High expression of TMEM40 is associated with the malignant behavior and tumorigenesis in bladder cancer.
    J Transl Med. 2018;16:9.
    Abstract    

    Abstract available

  158. BROUGHTON BL, Baron B, Kiernan M, Baack-Kukreja J, et al
    Cystectomy-Enhanced Recovery Program: Nursing Implications.
    Urol Nurs. 2017;37:9-14.
    Abstract    

    Abstract available

  159. NITTA S, Sakka S, Endo T, Komine M, et al
    [Fever, Hepatic Dysfunction and Interstitial Pneumonia Caused by Intravesical Bacillus Calmette-Guerin (BCG) Instillation after Urethral Bougie : A Case Report].
    Hinyokika Kiyo. 2017;63:427-430.
    Abstract    

    Abstract available

  160. OZAWA M, Kuromoto A, Morozumi K, Satou M, et al
    [Two Cases of Urachal Carcinoma Treated by TS-1/CDDP as Adjuvant Chemotherapy].
    Hinyokika Kiyo. 2017;63:413-419.
    Abstract    

    Abstract available

  161. IKEUCHI R, Sunada T, Yoshikawa T, Yoshida T, et al
    [Reactive Arthritis during the Second Course of Intravesical BCG Therapy Requiring Administration of Methotrexate : A Case Report].
    Hinyokika Kiyo. 2017;63:329-332.
    Abstract    

    Abstract available

  162. MATSUMOTO Y, Waku N, Kawai K, Ikeda A, et al
    [A Case of Primary Schwannoma of the Urinary Bladder].
    Hinyokika Kiyo. 2017;63:323-328.
    Abstract    

    Abstract available

  163. MINATO A, Fujimoto N, Kubo T
    Squamous Differentiation Predicts Poor Response to Cisplatin-Based Chemotherapy and Unfavorable Prognosis in Urothelial Carcinoma of the Urinary Bladder.
    Clin Genitourin Cancer. 2017;15:e1063-e1067.
    Abstract    

    Abstract available

  164. LEE CH, Ku JY, Jeong CW, Ku JH, et al
    Predictors for Intravesical Recurrence Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A National Multicenter Analysis.
    Clin Genitourin Cancer. 2017;15:e1055-e1061.
    Abstract    

    Abstract available

  165. SASAKI K, Wada K, Araki M, Kobayashi Y, et al
    Diagnostic Ureteroscopy for Cases Clinically Suspected of Carcinoma in Situ of the Upper Urinary Tract.
    Acta Med Okayama. 2017;71:227-232.
    Abstract    

    Abstract available

  166. SOUKUP V, Capoun O, Pesl M, Sobotka R, et al
    Placental Growth Factor in Bladder Cancer Compared to the Diagnostic Accuracy and Prognostic Performance of Vascular Endothelial Growth Factor A.
    Anticancer Res. 2018;38:239-246.
    Abstract    

    Abstract available

  167. MIYAKE M, Tatsumi Y, Matsumoto H, Nagao K, et al
    Outcomes of subsequent non-muscle invasive bladder cancer treated with intravesical Bacillus Calmette-Guerin after radical nephroureterectomy for upper urinary tract urothelial carcinoma: A propensity matched analysis with primary bladder cancer.
    BJU Int. 2017 Dec 27. doi: 10.1111/bju.14111.
    Abstract    

    Abstract available

  168. RITCH CR, Balise R, Soodana Prakash N, Alonzo D, et al
    Propensity matched comparative analysis of survival following chemoradiation or radical cystectomy for muscle invasive bladder cancer.
    BJU Int. 2017 Dec 27. doi: 10.1111/bju.14109.
    Abstract    

    Abstract available

  169. BOSSCHIETER J, van Moorselaar RJA, Vis AN, van Ginkel T, et al
    The Effect of Timing of an Immediate Instillation with Mitomycin C after Transurethral Resection in 941 Non Muscle-invasive Bladder Cancer Patients.
    BJU Int. 2018 Jan 10. doi: 10.1111/bju.14124.
    Abstract    

    Abstract available

  170. SEISEN T
    Examining the role of centralisation of radical cystectomy for bladder cancer.
    BJU Int. 2018;121:165-167.
    Abstract    



  171. CHOUDHURY A, Hoskin PJ
    Bladder cancer and the National Cancer Data Base: New insight or misinformation?
    Cancer. 2018 Jan 16. doi: 10.1002/cncr.31210.
    Abstract    



  172. VAN KESSEL KE, van der Keur KA, Dyrskjot L, Algaba F, et al
    Molecular markers increase precision of the European Association of Urology non-muscle invasive bladder cancer progression risk groups.
    Clin Cancer Res. 2018 Jan 24. pii: 1078-0432.CCR-17-2719.
    Abstract    

    Abstract available

  173. SAITO R, Kobayashi T, Ogawa O
    Re: Comprehensive Molecular Characterization of Muscle-invasive Bladder Cancer.
    Eur Urol. 2017 Dec 20. pii: S0302-2838(17)31042.
    Abstract    



  174. PANG KH, Noon AP
    Re: Radical Cystectomy (Bladder Removal) Against Intravesical BCG Immunotherapy for High-risk Non-muscle Invasive Bladder Cancer (BRAVO): A Protocol for a Randomised Controlled Feasibility Study.
    Eur Urol. 2017 Dec 19. pii: S0302-2838(17)31039.
    Abstract    



  175. YU Y, Jin H, Xu J, Gu J, et al
    XIAP overexpression promotes bladder cancer invasion in vitro and lung metastasis in vivo via enhancing nucleolin-mediated Rho-GDIbeta mRNA stability.
    Int J Cancer. 2017 Dec 18. doi: 10.1002/ijc.31223.
    Abstract    

    Abstract available

  176. FUJII Y
    Prediction models for progression of non-muscle-invasive bladder cancer: A review.
    Int J Urol. 2017 Dec 16. doi: 10.1111/iju.13509.
    Abstract    

    Abstract available

  177. CHANG SS
    Re: Increasing Age is Not Associated with Toxicity Leading to Discontinuation of Treatment in Patients with Urothelial Non-Muscle-Invasive Bladder Cancer Randomised to Receive 3 Years of Maintenance bacille Calmette-Guerin: Results from European Organ
    J Urol. 2018;199:26.
    Abstract    



  178. CHANG SS
    Re: Challenges in Pathologic Staging of Bladder Cancer: Proposals for Fresh Approaches of Assessing Pathologic Stage in Light of Recent Studies and Observations Pertaining to Bladder Histoanatomic Variances.
    J Urol. 2018;199:25-26.
    Abstract    



  179. NIWA N, Kikuchi E, Matsumoto K, Kosaka T, et al
    Purified protein derivative skin test prior to bacillus Calmette-Guerin therapy may have therapeutic impact in patients with non-muscle-invasive bladder cancer.
    J Urol. 2018 Jan 4. pii: S0022-5347(18)30006-5. doi: 10.1016/j.juro.2017.
    Abstract    

    Abstract available

  180. ZARGAR H, Shah JB, van Rhijn BW, Daneshmand S, et al
    Neoadjuvant dose dense MVAC versus GC in patients with cT3-4aN0M0 bladder cancer treated with radical cystectomy.
    J Urol. 2018 Jan 9. pii: S0022-5347(18)30036-3. doi: 10.1016/j.juro.2017.
    Abstract    

    Abstract available

  181. ATALA A
    Re: Mg(II)-Catechin Nanoparticles Delivering siRNA Targeting EIF5A2 Inhibit Bladder Cancer Cell Growth In Vitro and In Vivo.
    J Urol. 2017;198:258-259.
    Abstract    



  182. CHANG SS
    Re: Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guerin Therapy: Implication for Clinical Trial Design.
    J Urol. 2017;198:255.
    Abstract    



  183. CHANG SS
    Re: Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer.
    J Urol. 2018;199:341-342.
    Abstract    



  184. CHANG SS
    Re: The Impact of Re-Transurethral Resection on Clinical Outcomes in a Large Multicentre Cohort of Patients with T1 High-Grade/Grade 3 Bladder Cancer Treated with bacille Calmette-Guerin.
    J Urol. 2018;199:340-342.
    Abstract    



  185. FANTINI D, Glaser AP, Rimar KJ, Wang Y, et al
    A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer.
    Oncogene. 2018 Jan 25. pii: 10.1038/s41388-017-0099.
    Abstract    

    Abstract available

  186. MA J, Ge J, Xue X, Xiu W, et al
    Targeting bladder cancer using activated T cells armed with bispecific antibodies.
    Oncol Rep. 2018 Jan 11. doi: 10.3892/or.2018.6211.
    Abstract    

    Abstract available

  187. DEHAYNI Y, Tetou M, Khdach Y, Janane A, et al
    [Prognostic of older age for patients with invasive-muscle-bladder cancer and treated by radical cystectomy].
    Prog Urol. 2018 Jan 9. pii: S1166-7087(17)30679.
    Abstract    

    Abstract available

  188. ZUCCHI A, Costantini E
    "Nested Type" Bladder Cancer: Myth or Reality?
    Urol Int. 2018 Jan 17. pii: 000486533. doi: 10.1159/000486533.
    Abstract    



  189. XIA L, Taylor BL, Mamtani R, Christodouleas JP, et al
    Associations between Travel Distance, Hospital Volume, and Outcomes Following Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer.
    Urology. 2018 Jan 2. pii: S0090-4295(17)31331.
    Abstract    

    Abstract available

  190. ZHANG Z, Zhang G, Gao Z, Li S, et al
    Comprehensive analysis of differentially expressed genes associated with PLK1 in bladder cancer.
    BMC Cancer. 2017;17:861.
    Abstract    

    Abstract available

  191. HAN S, Kim D, Shivakumar M, Lee YJ, et al
    The effects of alternative splicing on miRNA binding sites in bladder cancer.
    PLoS One. 2018;13:e0190708.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;